Literature DB >> 24550394

Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-β (TGF-β) signaling promoting SMAD3 activation and fibrosis via Gremlin protein.

Steven O'Reilly1, Marzena Ciechomska, Rachel Cant, Jacob M van Laar.   

Abstract

Fibrosis is a common and intractable condition associated with various pathologies. It is characterized by accumulation of an excessive amount of extracellular matrix molecules that primarily include collagen type I. IL-6 is a profibrotic cytokine that is elevated in the prototypic fibrotic autoimmune condition systemic sclerosis and is known to induce collagen I expression, but the mechanism(s) behind this induction are currently unknown. Using healthy dermal fibroblasts in vitro, we analyzed the signaling pathways that underscore the IL-6-mediated induction of collagen. We show that IL-6 trans signaling is important and that the effect is dependent on STAT3; however, the effect is indirect and mediated through enhanced TGF-β signaling and the classic downstream cellular mediator Smad3. This is due to induction of the bone morphogenetic protein (BMP) antagonist Gremlin-1, and we show that Gremlin-1 is profibrotic and is mediated through canonical TGF-β signaling.

Entities:  

Keywords:  Cell Biology; Collagen; Extracellular; Fibrogenesis; Interleukin; Interleukin-6; Signal Transduction

Mesh:

Substances:

Year:  2014        PMID: 24550394      PMCID: PMC3975039          DOI: 10.1074/jbc.M113.545822

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

2.  Functional implications of the IL-6 signaling pathway in keloid pathogenesis.

Authors:  Mohammad Ghazizadeh; Mamiko Tosa; Hajime Shimizu; Hiko Hyakusoku; Oichi Kawanami
Journal:  J Invest Dermatol       Date:  2006-10-05       Impact factor: 8.551

3.  IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease.

Authors:  Doanh Le Huu; Takashi Matsushita; Guihua Jin; Yasuhito Hamaguchi; Minoru Hasegawa; Kazuhiko Takehara; Manabu Fujimoto
Journal:  J Invest Dermatol       Date:  2012-07-19       Impact factor: 8.551

4.  Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling.

Authors:  D A Frank; S Mahajan; J Ritz
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

5.  Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2.

Authors:  Stefania Mitola; Cosetta Ravelli; Emanuela Moroni; Valentina Salvi; Daria Leali; Kurt Ballmer-Hofer; Luca Zammataro; Marco Presta
Journal:  Blood       Date:  2010-07-21       Impact factor: 22.113

6.  Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma.

Authors:  H Ihn; S Sato; M Fujimoto; K Kikuchi; K Takehara
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

7.  Mice lacking the CNTF receptor, unlike mice lacking CNTF, exhibit profound motor neuron deficits at birth.

Authors:  T M DeChiara; R Vejsada; W T Poueymirou; A Acheson; C Suri; J C Conover; B Friedman; J McClain; L Pan; N Stahl; N Y Ip; G D Yancopoulos
Journal:  Cell       Date:  1995-10-20       Impact factor: 41.582

8.  Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.

Authors:  Takashi Matsushita; Minoru Hasegawa; Yasuhito Hamaguchi; Kazuhiko Takehara; Shinichi Sato
Journal:  J Rheumatol       Date:  2006-02       Impact factor: 4.666

9.  Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis.

Authors:  Robert J J O'Donoghue; Darryl A Knight; Carl D Richards; Cecilia M Prêle; Hui Ling Lau; Andrew G Jarnicki; Jessica Jones; Steven Bozinovski; Ross Vlahos; Stefan Thiem; Brent S McKenzie; Bo Wang; Philip Stumbles; Geoffrey J Laurent; Robin J McAnulty; Stefan Rose-John; Hong Jian Zhu; Gary P Anderson; Matthias R Ernst; Steven E Mutsaers
Journal:  EMBO Mol Med       Date:  2012-06-08       Impact factor: 12.137

Review 10.  Interleukin-6: a new therapeutic target in systemic sclerosis?

Authors:  Steven O'Reilly; Rachel Cant; Marzena Ciechomska; Jacob M van Laar
Journal:  Clin Transl Immunology       Date:  2013-04-12
View more
  87 in total

1.  Cross regulation between hypoxia-inducible transcription factor-1α (HIF-1α) and transforming growth factor (TGF)-ß1 mediates nickel oxide nanoparticles (NiONPs)-induced pulmonary fibrosis.

Authors:  Fenghua Qian; Mindi He; Weixia Duan; Lin Mao; Qian Li; Zhengping Yu; Zhou Zhou; Yong Zhang
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

2.  Connective tissue diseases: Nucleosomes and systemic sclerosis.

Authors:  Steven O'Reilly; Jacob M van Laar
Journal:  Nat Rev Rheumatol       Date:  2016-02-04       Impact factor: 20.543

3.  S-allyl-cysteine attenuates carbon tetrachloride-induced liver fibrosis in rats by targeting STAT3/SMAD3 pathway.

Authors:  Zhiqiang Gong; Huisheng Ye; Yu Huo; Lei Wang; Yanhong Huang; Min Huang; Xingxing Yuan
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

4.  AAV1.SERCA2a Gene Therapy Reverses Pulmonary Fibrosis by Blocking the STAT3/FOXM1 Pathway and Promoting the SNON/SKI Axis.

Authors:  Malik Bisserier; Javier Milara; Yassine Abdeldjebbar; Sarah Gubara; Carly Jones; Carlos Bueno-Beti; Elena Chepurko; Erik Kohlbrenner; Michael G Katz; Sima Tarzami; Julio Cortijo; Jane Leopold; Roger J Hajjar; Yassine Sassi; Lahouaria Hadri
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

5.  Endothelial fibrosis induced by suppressed STAT3 expression mediated by signaling involving the TGF-β1/ALK5/Smad pathway.

Authors:  Alvaro Becerra; Macarena Rojas; Alejandro Vallejos; Vicente Villegas; Lorena Pérez; Claudio Cabello-Verrugio; Felipe Simon
Journal:  Lab Invest       Date:  2017-07-24       Impact factor: 5.662

Review 6.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 7.  Pathogenesis of systemic sclerosis-current concept and emerging treatments.

Authors:  Masutaka Furue; Chikage Mitoma; Hiroki Mitoma; Gaku Tsuji; Takahito Chiba; Takeshi Nakahara; Hiroshi Uchi; Takafumi Kadono
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

Review 8.  The role of IL-6 in host defence against infections: immunobiology and clinical implications.

Authors:  Stefan Rose-John; Kevin Winthrop; Leonard Calabrese
Journal:  Nat Rev Rheumatol       Date:  2017-06-15       Impact factor: 20.543

9.  STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.

Authors:  Benjamin L Bryson; Damian J Junk; Rocky Cipriano; Mark W Jackson
Journal:  Cell Cycle       Date:  2016-11-28       Impact factor: 4.534

10.  B(effector)reaking bad in systemic sclerosis: role of a novel B cell subset.

Authors:  S O'Reilly; J van Laar
Journal:  Clin Exp Immunol       Date:  2020-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.